Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: The present invention includes a jig for installing a protection member to a portable electronic device and a guide jig device including the same. The jig includes a main body and retaining members formed to be elastically deformed and coupled or connected to the main body while surrounding a mounting space in which the portable electronic device formed in the main body is inserted. The guide jig device is advantageous in that it can be used for a portable electronic device that is manufactured and sold in a size relatively greater than the size of the portable electronic device disclosed before its release.

Abstract: The present invention relates to a guide apparatus for installing a protective film on a front surface of a portable electronic device. The guide apparatus according to one embodiment includes: a receiving plate on which the portable electronic device is placed such that a rear surface of the portable electronic device is in contact with the receiving plate; and a retainer for retaining both end corners of a first side of the portable electronic device such that the retainer is in close contact with the first side of the portable electronic device placed on the receiving plate. The retainer is constructed to have a plurality of retaining lengths on the receiving plate.

Abstract: The pharmaceutical composition according to the present invention contains the active ingredient dimethyl fumarate or monomethyl fumarate or a pharmaceutically acceptable salt thereof in a specific dose, and exhibits specific pharmacokinetic parameters when administered into the body. In addition, the pharmaceutical composition of the present invention has proven its efficacy and safety in type 2 diabetic nephropathy patients with albuminuria, and thus can be effectively used as a preventive or therapeutic agent for diabetic nephropathy.

Abstract: The present invention relates to a guide apparatus for installing a protective film on a front surface of a portable electronic device. The guide apparatus according to one embodiment includes: a receiving plate on which the portable electronic device is placed such that a rear surface of the portable electronic device is in contact with the receiving plate; and a retainer for retaining both end corners of a first side of the portable electronic device such that the retainer is in close contact with the first side of the portable electronic device placed on the receiving plate. The retainer is constructed to have a plurality of retaining lengths on the receiving plate.

Abstract: Provided is a communication method of an electronic device, including executing a web browser, requesting registration in an IP multimedia core network subsystem (IMS) using a first client associated with the web browser, and displaying, in a part of the web browser using the first client, information associated with a network to which the electronic device is connected.

Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.

Abstract: Provided is a communication method of an electronic device, including executing a web browser, requesting registration in an IP multimedia core network subsystem (IMS) using a first client associated with the web browser, and displaying, in a part of the web browser using the first client, information associated with a network to which the electronic device is connected.

Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.

Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.

Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.

Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.